Market revenue in 2023 | USD 320.3 million |
Market revenue in 2030 | USD 456.0 million |
Growth rate | 5.2% (CAGR from 2023 to 2030) |
Largest segment | Subunit vaccines |
Fastest growing segment | Subunit Vaccines |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Subunit Vaccines, Inactivated, Live Attenuated, MRNA vaccines, Viral vector vaccines |
Key market players worldwide | Serum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Sinovac Biotech Ltd, BioNTech SE ADR, AstraZeneca PLC, Moderna Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to vaccine market will help companies and investors design strategic landscapes.
Subunit vaccines was the largest segment with a revenue share of 34.12% in 2023. Horizon Databook has segmented the Sweden vaccine market based on subunit vaccines, inactivated, live attenuated, mrna vaccines, viral vector vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
Continuous developments by companies operating in the market are contributing to the market growth. For instance, in January 2021, Moderna announced a collaboration with Sweden’s Recipharn to manufacture and supply mRNA vaccines in the country.
In addition, in January 2020, the International Vaccine Institute (IVI) announced that the Swedish International Development Cooperation Agency will continue to support IVI’s aim to boost vaccine R&D with a contribution of USD 5.24 million over the next 5 years as part of the collaboration between IVI and the Swedish government.
Thus, such initiatives are anticipated to create growth opportunities in the market in the coming years. In September 2022, Valneva SE and VBI Vaccines, Inc. announced a collaboration focused on certain European markets. The purpose of this partnership is to facilitate the marketing and distribution of PreHevbri [Hepatitis B vaccine (recombinant, adsorbed)], the sole 3-antigen hepatitis B vaccine approved for use in Europe.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden vaccine market , including forecasts for subscribers. This country databook contains high-level insights into Sweden vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account